The University of Virginia Comprehensive Cancer Center is conducting a clinical research study for patients who are adults who are not able to improve their platelet count, despite platelet transfusions. There is currently no approved treatment for this condition. The purpose of this study is to learn whether infusions of a drug called isatuximab in this population may help platelet transfusions be more effective. Isatuximab is approved for the treatment of multiple myeloma (MM), a type of cancer, but not for this issue with platelets, so this use of the drug is investigational.
Participants in the study will receive isatuximab by intravenous infusion weekly for 4 weeks. Isatuximab will be given while the patient is in the clinic (outpatient). During study treatment, participants will have platelet transfusions according to standard clinical care and weekly physical exams. Participants will be asked to complete a questionnaire related to quality of life before, during, and after study treatment.
Participants will be followed even after they have completed the study treatment. Study-specific tests that are being done beyond standard of care will be provided at no cost to the patient/participant or his/her/their insurance.
Additional information can be found here:
No Compensation